A–LIST

1. Veklury® (remdesivir) 2. Tepezza® (-trbw) 3. Reblozyl® (luspatercept-aamt) Q1–Q3 2020 sales: $873 million Q1–Q3 2020 sales: $476.3 million Q1–Q3 2020 sales: $159 million Sponsor(s): Gilead Sciences Sponsor(s): Horizon Therapeutics Sponsor(s): Bristol Myers Squibb and Acceleron Pharma Type: SARS-CoV-2 nucleotide analog RNA Type: Insulin-like growth factor-1 receptor inhibitor Type: Erythroid maturation agent polymerase inhibitor Indication(s): Thyroid eye disease Indication(s): Anemia in adult patients with beta Indication(s): Adults and pediatric patients (12 years FDA Approval Date: January 21, 2020 thalassemia who require regular red blood cell (RBC) of age and older and weighing at least 40 kg) for the transfusions; anemia failing an erythropoiesis stimulating treatment of coronavirus disease 2019 (COVID-19) agent and requiring two or more RBC units over eight weeks requiring hospitalization in adult patients FDA Approval Date: October 22, 2020 FDA Approval Date: November 8, 2019

4. Ruxience™ (-pvvr) 5. Trodelvy™ (sacituzumab govitecan-hziy) 6. Adakveo® (crizanlizumab-tmca)

Q1–Q3 2020 sales: $78 million Q1–Q3 2020 sales: $73.0 million Q1–Q3 2020 sales: $71 million Sponsor(s): Pfizer Sponsor(s): Immunomedics Sponsor(s): Novartis Type: CD20-directed cytolytic antibody; biosimilar Type: Trop-2-directed antibody and topoisomerase Type: Selectin blocker to Rituxan® (rituximab), co-marketed by Genentech inhibitor conjugate Indication(s): Reduce the frequency of vaso-occlusive and Biogen Indication(s): Treatment of adults with metastatic crises in adults and pediatric patients aged 16 years Indication(s): Non-Hodgkin’s lymphoma, chronic triple-negative breast cancer who have received at least and older with sickle-cell disease lymphocytic leukemia, granulomatosis with two prior therapies for metastatic disease FDA Approval Date: November 15, 2019 polyangiitis, and microscopic polyangiitis (Trodelvy was granted accelerated approval) FDA Approval Date: July 23, 2019 FDA Approval Date: April 22, 2020

7. Ubrelvy® (ubrogepant) 8. REGEN-COV2 (casirivimab and imdevimab) 9. Zepzelca™ (lurbinectedin)

Q1–Q3 2020 sales: $60 million Q1–Q3 2020 sales: $40.2 million Q1–Q3 2020 sales: $36.9 million Sponsor(s): AbbVie Sponsor(s): Regeneron Pharmaceuticals Sponsor(s): Jazz Pharmaceuticals Type: Calcitonin gene–related peptide receptor Type: Combination or “cocktail” of two monoclonal antibodies Type: Alkylating drug designed to bind guanine res- antagonist Indication(s): Treatment of mild to moderate COVID-19 idues in the minor groove of DNA, forming adducts Indication(s): Acute treatment of migraine with or in adults, as well as in pediatric patients at least 12 years and resulting in a bending of the DNA helix toward the without aura in adults of age and weighing at least 40 kg, who have received major groove FDA Approval Date: December 23, 2019 positive results of direct SARS-CoV-2 viral testing and are Indication(s): Treatment of adults with metastatic at high risk for progressing to severe COVID-19 small-cell lung cancer with disease progression FDA Approval Date: November 21, 2020 FDA Approval Date: June 15, 2020

10. Nurtec™ ODT (rimegepant) 11. Sarclisa® (-irfc) 12. Qinlock® (ripretinib)

Q1–Q3 2020 sales: $28.513 million Q1–Q3 2020 sales: €18 million ($22 million) Q1–Q3 2020 sales: $20.0 million Sponsor(s): Biohaven Pharmaceuticals Sponsor(s): Sanofi Sponsor(s): Deciphera Pharmaceuticals Type: Calcitonin gene–related peptide receptor Type: CD38-directed cytolytic antibody Type: Tyrosine kinase inhibitor targeting KIT proto- antagonist Indication(s): Multiple myeloma in adults who have oncogene receptor tyrosine kinase and platelet de- Indication(s): Acute treatment of migraine with or received at least two prior therapies including rived growth factor receptor alpha kinase without aura in adults lenalidomide and a proteasome inhibitor, in combination Indication(s): Treatment of adults with advanced FDA Approval Date: February 27, 2020 with pomalidomide and dexamethasone gastrointestinal stromal tumor who have received prior FDA Approval Date: March 2, 2020 treatment with three or more kinase inhibitors FDA Approval Date: May 15, 2020

13. Tabrecta™ (capmatinib) 14. Retevmo™ (selpercatinib) 15. Ayvakit™ (avapritinib)

Q1–Q3 2020 sales: $18 million Q1–Q3 2020 sales: $17.9 million Q1–Q3 2020 sales: $15.3 million Sponsor(s): Novartis Sponsor(s): Eli Lilly and Company Sponsor(s): Blueprint Medicines Type: Kinase inhibitor targeting MET, including the Type: Kinase inhibitor targeting wild-type RET and multiple Type: Tyrosine kinase inhibitor targeting PDGFRA and mutant variant produced by exon 14 skipping mutated RET isoforms as well as VEGFR1 and VEGFR3 with PDGFRA D842 mutants as well as multiple KIT exon 11, IC values ranging from 0.92 nM to 67.8 nM Indication(s): Treatment of adult patients with meta- 50 11/17, and 17 mutants with IC50 values below 25 nM static non-small cell lung cancer whose tumors have Indication(s): Forms of non-small cell lung cancer Indication(s): Unresectable or metastatic gastrointesti- a mutation that leads to mesenchymal-epithelial (adults), medullary thyroid cancer, and other types of nal stromal tumor harboring a platelet-derived growth transition (MET) exon 14 skipping as detected by an thyroid cancers whose tumors have a mutation or fusion factor receptor alpha exon 18 mutation FDA-approved test in the RET (rearranged during transfection) gene FDA Approval Date: January 9, 2020 FDA Approval Date: May 6, 2020 FDA Approval Date: May 8, 2020

GENengnews.com | Genetic Engineering & Biotechnology News | FEBRUARY 2021 | 19